Insights

Strategic Partnerships Leverage recent collaborations with Visus/VISUfarma and Lupin to expand geographic reach and accelerate market access in Europe and other major markets through co-promotion, distribution agreements, and combined ophthalmology portfolios.

Presbyopia Franchise Position YUVEZZI as a first-to-market dual-agent solution for presbyopia with large US and global addressable populations; target ophthalmology clinics and optometry networks with education campaigns highlighting convenience and real-world patient benefits.

Manufacturing & scale Capitalize on established manufacturing partnerships (Ritedose) to support supply reliability and single-source readiness for growing demand; offer contract manufacturing opportunities to regional partners to reduce lead times and ensure compliant distribution.

Direct-to-Patient Access Promote the DTP program to streamline patient access, transparent pricing, and home delivery; engage patient support services teams and PBMs to secure formulary inclusion and favorable reimbursement terms.

Leadership & Milestones Highlight leadership’s ophthalmic track record and recent CMO appointment to build credibility with payers and healthcare providers; align messaging with upcoming regulatory milestones and new product launches to create a compelling growth narrative.

Similar companies to Tenpoint Therapeutics, Ltd.

Tenpoint Therapeutics, Ltd. Tech Stack

Tenpoint Therapeutics, Ltd. uses 8 technology products and services including Power BI, Tableau, Microsoft SharePoint, and more. Explore Tenpoint Therapeutics, Ltd.'s tech stack below.

Media & News

Tenpoint Therapeutics, Ltd.'s Email Address Formats

Tenpoint Therapeutics, Ltd. uses at least 3 email formats:
Tenpoint Therapeutics, Ltd. Email FormatsExamplePercentage
First.Last@visustx.comJohn.Doe@visustx.com
98%
First@visustx.comJohn@visustx.com
1%
FLast@visustx.comJDoe@visustx.com
1%

Frequently Asked Questions

What is Tenpoint Therapeutics, Ltd.'s official website and social media links?

Minus sign iconPlus sign icon
Tenpoint Therapeutics, Ltd.'s official website is tenpointtherapeutics.com and has social profiles on LinkedIn.

How much revenue does Tenpoint Therapeutics, Ltd. generate?

Minus sign iconPlus sign icon
As of October 2026, Tenpoint Therapeutics, Ltd.'s annual revenue is estimated to be $50M - $100M.

What is Tenpoint Therapeutics, Ltd.'s NAICS code?

Minus sign iconPlus sign icon
Tenpoint Therapeutics, Ltd.'s NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Tenpoint Therapeutics, Ltd. have currently?

Minus sign iconPlus sign icon
As of October 2026, Tenpoint Therapeutics, Ltd. has approximately 128 employees across 2 continents, including North America and Europe. Key team members include Chief Executive Officer: H. B., Chief Technology Officer: G. R. and Chief Technology Officer: G. R. Explore Tenpoint Therapeutics, Ltd.'s employee directory with LeadIQ.

What industry does Tenpoint Therapeutics, Ltd. belong to?

Minus sign iconPlus sign icon
Tenpoint Therapeutics, Ltd. operates in the Pharmaceutical Manufacturing industry.

What technology does Tenpoint Therapeutics, Ltd. use?

Minus sign iconPlus sign icon
Tenpoint Therapeutics, Ltd.'s tech stack includes Power BI, Tableau, Microsoft SharePoint, Microsoft 365, Microsoft Intune, Webflow, WP Engine and Microsoft Teams.

What is Tenpoint Therapeutics, Ltd.'s email format?

Minus sign iconPlus sign icon
Tenpoint Therapeutics, Ltd.'s email format typically follows the pattern of First.Last@visustx.com. Find more Tenpoint Therapeutics, Ltd. email formats with LeadIQ.

How much funding has Tenpoint Therapeutics, Ltd. raised to date?

Minus sign iconPlus sign icon
As of October 2026, Tenpoint Therapeutics, Ltd. has raised $56M in funding. The last funding round occurred on Aug 10, 2021.

When was Tenpoint Therapeutics, Ltd. founded?

Minus sign iconPlus sign icon
Tenpoint Therapeutics, Ltd. was founded in 2019.
Tenpoint Therapeutics, Ltd. logo

Tenpoint Therapeutics, Ltd.

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

Tenpoint Therapeutics, Ltd. is a global ophthalmic pharmaceutical company based in Irvine, California, focused on bringing solutions to the aging eye. Its lead product, YUVEZZI, combines carbachol and brimonidine tartrate in a single eye drop for presbyopia, and is positioned as the first and only dual-agent therapy for this condition. The company targets adults with presbyopia and aims to address real-world needs by working with eye care professionals to support access to treatment. Operating in the pharmaceutical manufacturing and commercialization arena, Tenpoint emphasizes a global reach in its ophthalmic portfolio.

YUVEZZI became available in the United States in March 2026, marking a key product launch for the company. The organization describes itself as a global commercial ophthalmic company with leadership drawn from the field, underscoring its focus on advancing vision restoration for the aging population.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2019
Employees
51-200

Section iconFunding & Financials

  • $56M

    Tenpoint Therapeutics, Ltd. has raised a total of $56M of funding over 2 rounds. Their latest funding round was raised on Aug 10, 2021 as a Debt Financing.

  • $50M - $100M

    Tenpoint Therapeutics, Ltd.'s revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.